ARCHIVES

In Brief: FDA commissioner Kessler To Resign, Says His Goals Were Accomplished

This article is from The Cancer Letter archive.

Vol. 22 No. 46 | November 29, 1996

Download PDF Visit The Full Archive

Related Articles

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

Also in this 8-page issue: M.D. Anderson Cancer Center wins ninth SPORE grant, this time for melanoma research.

October 22, 2004

Investigators Unlocking Drug Resistance Secrets, NCI Study, Bristol-Myers Meeting Reports Show

November 28, 1986

Cancer Commission Surveying for Pill, Hepatoma Association

October 1, 1976

Three Nurse Awards Made In Self Care

September 30, 1988

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012